您現在的位置 :

醫療團隊

專業的醫護人員，提供最佳的醫療服務

醫師介紹

  •

盧勝男醫師

肝炎、肝硬化、肝癌、職業性肝病、超音波導引介入治療、肝腫瘤消融治療
  • 國語,英語,閩南語
  • 教授
醫師網路掛號
直接點選進入醫師網路掛號畫面
醫師資歷
  • 現職
    • 高雄長庚紀念醫院 胃腸肝膽科系顧問級主治醫師 (2024.09~)
    • 長庚大學 醫學系專任教授 (2024.02~)
    • 台灣腫瘤消融醫學會 名譽理事長 (2018.02~)
    • 社團法人台灣肝病醫療策進會 理事
    • 衛生福利部 肝癌及肝炎防治會委員 (2011~)
    • 台灣肝臟研究學會(TASL)執行委員(2018~)暨基金會董事(2019~)
    • Asia Society on Tumor Ablation (ASTA), board member (2019~)
    • 嘉義縣政府 縣政顧問 (2021-2024)
    • 成功大學 醫學系 公共衛生學科暨研究所 兼任教授 (2021.08~)
    • 中山大學 臨床醫學科技博士學位學程 合聘教授 (2023.08~)
  • 學歷
    • 高雄醫學院醫學系醫學士 (1984)
    • 台灣大學醫學院公共衛生研究所預防醫學組公共衛生碩士 (1986)
    • 高雄醫學院醫學研究所博士班醫學博士 (1992)
  • 經歷
    • 長庚大學 醫學院醫學系兼任教授 (2017.08~2024.01)
    • 高雄長庚紀念醫院 副院長 (2020.07~2023.06)
    • 嘉義長庚紀念醫院 副院長 (2017.07~2020.06)
    • 台灣腫瘤消融醫學會名譽理事長 (2018~)
    • Host Chair, 6th Asia Conference of Tumor Ablation (ACTA2019) (2019)
    • 長庚大學醫學系與臨床醫學研究所 合聘專任教授 (2008.08~2017.07)
    • 高雄長庚紀念醫院 內科部副部主任 (2016-2017)
    • 高雄長庚紀念醫院 職業醫學科主任 (2004.12-2012.7)
    • 高雄長庚紀念醫院 胃腸肝膽科主任 (1999-2002)
    • 高雄長庚紀念醫院 胃腸肝膽科系副教授級主治醫師 (1997-2007)
    • 華濟醫院 肝膽胰內科主任 (1996-1997)
    • 高雄醫學院 醫學系 內科學講師 (1990~1996)
    • 高雄醫學院附設中和紀念醫院 肝膽胰內科主治醫師 (1990-1996)
    • 高雄醫學院附設中和紀念醫院 內科住院醫師 (1986~1990)
    • 台灣肝癌醫學會(TLCA）第1屆理事.第2屆理事.第3屆監事.第4屆常務理事.第5屆監事.第6屆理事(2008-2023)
    • 高雄市肝病防治協會 第一屆、第二屆 (2012~2016)、第五屆、第六屆理事長(2020~2023)
    • 台灣腫瘤消融醫學會(TATA) 第一屆、第二屆理事、第三屆理事長
    • 中華民國醫用超音波學會 第十三屆常務理事 (2006.11~2008.10)
    • 嘉義市政府 市政顧問 (2017.11~2018.12)
    • 衛生福利部 國家消除C型肝炎辦公室流行病學研究組組長 (2016~2023)
    • 台灣消化系醫學會(GEST) 理事 (2015~2024.03)
  • 學會與認證
    • 台灣內科醫學會 內科專科醫師、指導醫師
    • 台灣消化系醫學會 消化系內科專科醫師、指導醫師
    • 台灣消化系內視鏡醫學會 消化系內視鏡專科醫師
    • 中華民國職業醫學會 職業醫學專科醫師、指導醫師
    • 中華民國醫用超音波學會 超音波專業醫師、指導醫師
    • 台灣肝癌醫學會專科醫師
    • 台灣腫瘤消融學會 認證肝腫瘤消融手術醫師
  • 論文及期刊發表
    • Ding YJ, Chang TS, Shen CH, Kuo LM, Hsu SL, Chen YH, Hsieh YY, Huang HL, Lu SN*. Survival benefit of sequential curative treatment for TACE suitable BCLC stage B HCC patients. Sci Rep. 2024 Sep 29;14(1):22588.

    • Huang HL, Chang TS, Canseco LM, Wu F*, Lu SN*. Role of reimbursement and Physicians' awareness in the survival of sorafenib-eligible advanced hepatocellular carcinoma patients. Kaohsiung J Med Sci. 2024 Jun;40(6):589-598. doi: 10.1002/kjm2.12838. (SCI)
      健保給付和醫師認知對於符合蕾莎瓦適應症晚期肝癌病人的生存效益所扮演的角色
      doi: 10.1002/kjm2.12838.
    • Chen CH, Hsu NT, Chen IC, Chang TS, Cheng S, Cheng SY, Chen HM, Harn MR, Liu CK, Yang MT, Lu SL, Tseng CM*, Lu SN*. Dual strategy involving hospital-based study and community-based screening to eliminate hepatitis C in remote areas. J Formos Med Assoc. 2024 May; 123(5): 613-619. (SCI)
      醫院內研究加上社區篩檢雙重策略消除偏遠地區的C型肝炎
      https://doi.org/10.1016/j.jfma.2024.01.005
    • Wang JH, Ou HY, Yen YH, Hung CH, Lu SN*. Usefulness of controlled attenuation parameter in monitoring clinically relevant decline of hepatic steatosis for non-alcoholic fatty liver disease. Liver Int. 2023 Sep;43(9):1901-1908. (SCI)
      可控衰減參數監測非酒精脂肪肝病患達具臨床意義的肝臟脂肪量減少的效用
    • Yao CC, Wang JH, Chen CH, Hung CH, Yen YH, Kee KM, Hu TH, Tsai MC, Kuo YH, Lu SN*. Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Diagnostics. 2023 Feb;13(4):696. (SCI)
      DCP 較短的降解半衰期是一個針對肝細胞癌病患經射頻腫瘤燒灼局部治療優秀的臨床運用評估療效指標
    • Kee KM, Chen CH, Hu JT, Huang YH, Wang TE, Chau GY, Chen KH, Chen YL, Lin CC, Hung CF, Huang SF, Liu TW, Ku HY, Huang BS, Wang YP, Tseng HP, Chiang CJ, Lu SN*. Secular Trends of Clinical Characteristics and Survival of Hepatocellular Carcinoma in Taiwan from 2011 to 2019. Viruses. 2022 Dec 31;15(1):126. (SCI)
      臺灣2011年至2019年肝細胞癌臨床特徵及存活率的年代趨勢
    • Chang TS, Hsu NT, Chen SC, Hsu IL, Lee MH, Lu SN*. Non-B, Non-C Hepatocellular Carcinoma in an HBV- and HCV-Endemic Area: A Community-Based Prospective Longitudinal Study. Viruses. 2022 May 7;14(5):984.(SCI)

    • Chuang PH, Lu SN*. Sequential treatment after transcatheter arterial chemoembolization for patients with single large hepatocellular carcinoma. Adv Dig Med. 2022;9:141-143. (EDITORIAL) 台灣消化醫學雜誌 (non-SCI)

    • Wu CH, Huang WC, Chen CH, Lu SN*. Outcomes of hepatitis B immunoglobulin and hepatitis B vaccination in high-risk newborns born to HBeAg-positive mothers. Biomed J. 2022 Oct;45(5):798-805. (SCI)
      B型肝炎免疫球蛋白及疫苗對於HBEAG陽性媽媽所生之高危險新生兒之預後影響
    • Lin SH, Lin CY, Hsu NT, Yen YH, Kee KM, Wang JH, Hu TH, Chen CH, Hung CH, Chen CH, Hu JT, Huang YH, Wang TE, Lu SN*. Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information. J Formos Med Assoc. 2022 Oct;121(10):2085-2092. (SCI)
      使用大規模全國數據和醫學中心數據重新評估甲型胎蛋白在肝細胞癌監測中的角色
    • Kee KM, Chen WM, Hsu NT, Wang JH, Chao WH, Lin YC, Lu SN*. Community-based screening by Anti-HCV reflex HCV Ag test and accessible post-screening care toward elimination of hepatitis C in two hyperendemic townships. J Formos Med Assoc. 2022 Sep;121(9):1850-1856. (SCI)
      在兩個高盛行城鎮用C肝抗體篩檢接續C肝抗原檢測做社區篩檢和篩檢後可近性照顧以根除C型肝炎
    • Tien HM, Cheng TC(co-first), Lien HC, Yang KF, Shy CG, Chen YL, Hsu NT, Lu SN*, Wang JH*. Liver Disease Screening and Hepatitis C Virus Elimination in Taiwan Rural Indigenous Townships: Village-By-Village Screening and Linking to Outreach Hepatology Care. Int J Environ Res Public Health. 2022 Mar 10;19(6):3269. (non-SCI)
      台灣偏遠原住民鄉肝病篩檢及Ｃ型肝炎消除- 逐村篩檢及連結外展肝病專科門診的照護模式
    • Huang WC, Lin YC, Chen PJ, Hsu NT, Tu CL, Chang TS, Hung CH, Kee KM, Chao WH, Lu SN*. Community-Based Screening for Hepatitis B and C Infectivity Using Two Quantitative Antigens to Identify Endemic Townships. Viruses. 2022 Feb 1;14(2):304. (SCI)
      用兩種抗原定量檢測進行社區傳染性B及C肝篩檢找出盛行鄉鎮
    • Lee YC, Wang JH, Chen CH, Hung CH, Lo KC, Yen YH, Kee KM, Hu TH, Lu SN*, Kuo YH*. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study. Kaohsiung J Med Sci. 2021 Oct;37(10):894-902. (SCI)
      蕾莎瓦在Ｂ型肝炎病毒或C型肝炎病毒相關的肝癌中使用的結果：傾向分數配對研究
    • Chang TS, Chang KC, Chen WM, Hsu NT, Lee CY, Lin YC, Huang WC, Chiu WN, Hu JH, Huang TJ, Chen MY, Lu SN*. Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study. BMJ Open. 2021 Jul 7;11(7):e046115. (SCI)

    • Wu GH, Yang WW, Liu CL, Pwu RF, Chien RN, Lee PC, Chen SC, Chen DS, Lu SN*. The epidemiological profile of chronic hepatitis C with advanced hepatic fibrosis regarding virus genotype in Taiwan: A nationwide study. J Formos Med Assoc. 2021 July ; 120(7): 1444-1451. (SCI)
      嚴重纖維化之慢性C型肝炎病患病毒基因型之流行病學剖析：全國性的研究
    • Chen WM, Lee CY, Hsu NT, Huang WC, Chen MY, Huang TJ, Lu SN*. Feasibility of anti-HCV reflex HCV Ag screening strategy in an HCV endemic community. J Formos Med Assoc. 2021 May;120(5):1237-1241. (SCI)
      C型肝炎抗體合併核心抗原用於C型肝炎高盛行區篩檢之可行性
    • Lu SN*, Wu HM, Pwu RF. : Alternate title: Epidemiology-based precise hepatitis C pilot control programs leads the official national screening. Taiwan Journal of Public Health. 2021 Apr; 40(2):123-126. 台灣公共衛生雜誌 (政策論壇 Policy Forum)
      依據流行病學的精準C肝防治先導計劃引領全國性篩檢
    • Chang KC, Lee CY, Chang TS, Hung CH, Chen WM, Chen MY, Huang TJ, Chiu WN, Hu JH, Lin YC, Huang WC, Hsu NT, Lu SN*. Usefulness of quantitative hepatitis B surface antigen testing in hepatitis B community-based screening. J Formos Med Assoc . 2021 Feb;120(2):847-853. (SCI)

    • Tsao CF, Chang CM, Weng SW, Wang PW, Lin CY, Lu SN. Identifying endemic areas and estimating the prevalence of hyperlipidemia in Taiwan's townships. J Formos Med Assoc. 2021 Jan;120(1 Pt 2):460-465. (SCI)
      評估台灣鄉鎮的高血脂症的流行地區及盛行率
    • Chen YY, Chen CL, Chen JW, Hsu NT, Wei ST, Hou SM, Lu SN*, Chen PJ*. Secular Trends and Geographic Maps of Hepatitis C Virus Infection among 4 Million Blood Donors in Taiwan from 1999 to 2017. Hepatol Commun. 2020 Jun 4;4(8):1193-1205.
      1999至2017年間台灣四百萬捐血者的分布地圖及長期趨勢
    • Wang JH, Ou HY, Yen YH, Chen CH, Lu SN*. Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference. Dig Dis Sci. 2020 May;65(5):1512-1519. (SCI)
      以核磁共振-肝臟氫核密度肥胖分數為標準評估肝纖維掃描可控衰減參數對肝臟脂肪嚴重度及變化的使用
    • Wang JH, Chen CH, Chang CM, Feng WC, Lee CY, Lu SN*. Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan. J Formos Med Assoc. 2020 Jan;119(1 Pt 3):504-508. (SCI)
      C型肝炎核心抗原是社區篩檢活動性C型肝炎經濟有效的工具
    • Wang JH, Hu TH, Chen CH, Hung CH, Yen YH, Chang KC, Lu SN*. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent. Kaohsiung J Med Sci. 2019 Nov;35(11):708-714. (SCI)
      B型肝炎相關肝硬化病人抗病毒治癒達完全病毒反應時肝硬度測量對肝癌發生的預測
    • Kuo YH, Kee KM, Hsu NT, Wang JH, Hsiao CC, Chen Y, Lu SN*. Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening. PLoS One. 2019 Oct 22;14(10):e0222196. (SCI)
      在大型社區篩檢，使用APRI和FIB4來偵測慢性C型肝炎
    • Lu SN. Liver Tumor Ablation Assisted by Image Fusion. J Med Ultrasound. 2019 Apr-Jun;27(2):61-62. (Non-SCI) 醫用超音波雜誌

    • Kuo YH, Lu SN*. Letter: the association between chronic viral hepatitis and metabolic syndrome - Authors' reply. Aliment Pharmacol Ther. 2019 Jan;49(2):233-234. (SCI)

    • Chang C, Hung CH, Wang JH, Lu SN*. Hepatitis C core antigen highly correlated to HCV RNA. Kaohsiung J Med Sci. 2018 Dec;34(12):684-688. (SCI)

    • Kuo YH, Lu SN*. Editorial: hepatitis B, fatty liver and metabolic syndrome-Interaction or co-existence? Authors' reply. Aliment Pharmacol Ther. 2018 Nov;48(10):1162-1163. (SCI)

    • Kuo YH, Kee KM, Wang JH, Hsu NT, Hsiao CC, Chen Y, Lu SN*. Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study. Aliment Pharmacol Ther. 2018 Nov;48(9):993-1002 (SCI)

    • Yen CW, Kuo YH, Wang JH, Chang KC, Kee KM, Hung SF, Chen Y, Tsai LS, Chen SC, Hung CH, Lu SN*. Did AFP-L3 save ultrasonography in community screening? Kaohsiung J Med Sci. 2018 Oct;34(10):583-587. (SCI)

    • Kuo YH, Wu IP, Wang JH, Hung CH, Rau KM, Chen CH, Kee KM, Hu TH, Lu SN*. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. Invest New Drugs. 2018 Apr;36(2):307-314. (SCI)

    • Kuo YH, Wang JH, Hung CH, Rau KM, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN*. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. J Gastroenterol Hepatol. 2017 Dec;32(12):1975-1981. (SCI)

    • Wu CH, Hsu TY, Kung FT, ChangChien CC, Tsai CC, Lu SN*. Changes in the Prevalence of HBsAg and HBeAg: a Study of 8696 Parturients in a Well Vaccinated Area. Sci Rep. 2017 Apr 27;7(1):1212.(SCI)

    • Kee KM, Lu SN*. Diagnostic efficacy of ultrasound in hepatocellular carcinoma diagnosis. Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):277-279. (Editorial)

    • Chien TL, Wang JH, Kee KM, Chen CH, Hung CH, Lu SN*. Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function. PLoS One. 2016 Dec 9;11(12):e0166543. (SCI)

    • Wang JH, Yen YH, Yao CC, Hung CH, Chen CH, Hu TH, Lee CM, Lu SN*. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy. Liver Int. 2016 Dec;36(12):1793-1799.(SCI)
      以肝纖維化測量為基礎的分數預測慢性C型肝炎病人治療成功後的肝癌發生風險
    • Kee KM, Wang JH, Wang CC, Cheng YF, Lu SN*. Hepatocellular Carcinoma associated with Extra-hepatic Primary Malignancy: its Secular change, Clinical Manifestations and Survival. Sci Rep. 2016 Jul 22;6:30156. (SCI)

    • Yeh JH, Hung CH, Wang JH, Kuo YH, Tai WC, Lu SN*. Hepatocellular carcinoma detected by regular surveillance: Does timely confirmation of diagnosis matter? Dig Liver Dis. 2016 June;48(6):661-666. (SCI)

    • Kuo YH, Tsai MC, Kee KM, Chang KC, Wang JH, Lin CY, Lin SC, Lu SN*. Associated Factors for Metabolic Syndrome in the Older Adults with Chronic Virus Hepatitis in the Community. PLoS One. 2016 May 13;11(5):e0155544. (SCI)
      社區老年慢性肝炎者有代謝症候群的相關因子
    • Wang JH(co-first), Chen TY(co-first), Ou HY, Wang CC, Liu YW, Hung CH, Chen CH, Kuo CH, Hu TH, Cheng YF, Lu SN*. Clinical Impact of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging on Hepatoma Management: A Prospective Study. Dig Dis Sci. 2016 Apr;61(4):1197-205. (SCI)
      Primovist 核磁共振檢查影響肝癌臨床處理的前瞻研究
    • Yap YS, Chuang KW, Chiang CJ, Chuang HY, Lu SN*. Geographic Variation of Chronic Kidney Disease Prevalence: Correlation with the Incidence of Renal Cell Carcinoma or Urothelial Carcinoma? Biomed Res Int. 2015;2015:427084. (SCI)

    • Yeh JH, Hung CH, Wang JH, Chen CH, Kee KM, Kuo CM, Yen YH, Cheng YF, Chen YY, Hsu HC, Lu SN*. Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment. PLoS One. 2015 Dec 14;10(12):e0144893. (SCI)

    • Kuo YH, Lu SN*. Role of serum quantitative hepatitis B surface antigen (HBsAg) in HBsAg carriers in a follow-up community study. Kaohsiung J Med Sci. 2015 July; 31(7):386-387. (SCI)
      (letter)
    • Kuo YH, Chen PF, Wang JH, Chang KC, Kee KM, Tsai MC, Lin CY, Lin SC, Tsai LS, Chen SC, Lu SN*. Comparison Stratagems of Post-Screening Management of Anti-HCV-Positive Community Residents: Simple Notification, Active Referral, or Accessible Medical Care. PLoS One. 2015 May 13;10(5):e0126031. (SCI)

    • Wang JH, Kee KM, Lin CY, Hung CH, Chen CH, Lee CM, Lu SN*. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. J Gastroenterol Hepatol. 2015 Feb;30(2):358-63. (SCI)

    • Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Lu SN*. Changing serum levels of quantitative hepatitis B surface antigen and hepatitis B virus DNA in hepatitis B virus surface antigen carriers: A follow-up study of an elderly cohort. Kaohsiung J Med Sci. 2015 Feb; 31(2): 102–107. (SCI)

    • Lee MH*, Lu SN*, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L'Italien G, Chen CJ*; R.E.V.E.A.L.-HCV Study Group. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One. 2014 May 6;9(5):e94760. (SCI)

    • Kee KM, Hung CH, Wang JH, Lu SN*. Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib. OncoTargets and Therapy. 2014 May;7:829-834. (SCI)

    • Kee KM, Wang JH, Lin CY, Wang CC, Cheng YF, Lu SN*. Validation of the 7th edition TNM staging system for hepatocellular carcinoma: an analysis of 8,828 patients in a single medical center. Dig Dis Sci. 2013 Sep;58(9):2721-8. (SCI)

    • Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Lu SN. Improvement of Thrombocytopenia in Hepatitis C-Related Advanced Fibrosis Patients After Sustained Virological Response. Dig Dis Sci. 2013 Feb;58(2):556-61. (SCI)

    • Chen CT, Chen JY, Wang JH, Chang KC, Tseng PL, Kee KM, Chen PF, Tsai LS, Chen SC, Lin SC, Lu SN*. Diabetes mellitus, metabolic syndrome and obesity are not significant risk factors for hepatocellular carcinoma in an HBV- and HCV-endemic area of Southern Taiwan. Kaohsiung J Med Sci. 2013 Aug;29(8):451-9. (SCI)

    • Tseng PL, Wang JH, Hung CH, Tung HD, Chen TM, Huang WS, Liu SL, Hu TH, Lee CM, Lu SN*. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations. Kaohsiung J Med Sci. 2013 Jul;29(7):385-95. (SCI)

    • Wang JH, Lu SN*. Response to Giannini et al. Am J Gastroenterol. 2013 Jul;108(7):1175. (SCI)

    • Chen CH, Lee CM, Wang JH, Hu TH, Hung CH, Changchien CS, Lu SN*. Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion. Hepatol Int. 2013 June;7(2):477-488. (SCI)

    • Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH, Tai WC, Tsai LS, Chen SC, Lin SC, Lu SN*. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol. 2013 Mar;108(3):416-24. (SCI)

    • Wang JH, Wang CC(co-first), Hung CH, Chen CL, Lu SN*. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2012 Feb;56(2):412-8. (SCI)

    • Liu JL, Chen JY, Chen CT, Wang JH, Lin CY, Chen PF, Hung CH, Kee KM, Lee CM, Tsai LS, Chen SC, Lin SC, Lu SN*. Community-based cross-sectional study: the association of lipids with hepatitis C seropositivity and diabetes mellitus. J Gastroenterol Hepatol. 2012 Nov;27(11):1688-94. (SCI)

    • Lu SN. Cross-stage and combination treatment for Barcelona Clinic of Liver Cancer stage B (intermediate stage) hepatocellular carcinoma. J Gastroenterol Hepatol. 2012 Jun;27(6):991-3. (SCI)

    • Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Chen CH, Lu SN*. Is hepatitis C virus core antigen an adequate marker for community screening? J Clin Microbiol. 2012 Jun;50(6):1989-93. (SCI)

    • Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Chang KC, Tseng PL, Yen YH, Lin CY, Lu SN*. Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study. J Gastroenterol Hepatol. 2012 Jun;27(6):1106-11. (SCI)

    • Kee KM, Lu SN*. Hospital- and community-based screenings for hepatocellular carcinoma in Taiwan. Oncology. 2011;81 Suppl 1:36-40. (SCI)

    • Tsai PS, Chang CJ, Chen KT, Chang KC, Hung SF, Wang JH, Hung CH, Chen CH, Tseng PL, Kee KM, Yen YH, Tsai CC, Lu SN*. Acquirement and disappearance of HBsAg and anti-HCV in an aged population: a follow-up study in an endemic township. Liver Int. 2011 Aug;31(7):971-9. (SCI)

    • Chen CT, Kuo YH, Huang CF, Huang CF, Lu SN*. Treatment Effects of Standard of Care for Chronic Hepatitis C in Real World: A Personal Experience of A Hepatologist in A Medical Center in Southern Taiwan. J Intern Med Taiwan 2011 June; 22(3): 192-198. 內科學誌
      慢性C型肝炎標準照顧在臨床上的療效：南台灣醫學中心某醫師的經驗
    • Hung CH, Lee CM, Lu SN*. Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Expert Rev Anti Infect Ther. 2011 May;9(5):525-33. Review. (SCI)

    • Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN*. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients. J Gastroenterol Hepatol. 2011 Mar;26(3):461-8. (SCI)

    • Hung CH, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, Lu SN*. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer. 2011 May 15;128(10):2344-52. (SCI)

    • Huang YC, Huang CF, Chang KC, Hung SF, Wang JH, Hung CH, Chen CH, Tseng PL, Kee KM, Yen YH, Tsai PS, Tsai CC, Lu SN*. Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B- and C-endemic area. J Gastroenterol Hepatol. 2011 Jan;26(1):129-34. (SCI)

    • Wang JH, Tung HD, Chen TY, Hung CH, Chen CH, Changchien CS, Hu TH, Lee CM, Lu SN*. Radiofrequency ablation of small hepatocellular carcinoma with intravenous pegylated liposomal doxorubicin. Hepatol Int. 2011 Mar; 5(1): 567-574. (SCI)

    • Chen JY, Wang JH, Lin CY, Chen PF, Tseng PL, Chen CH, Chang KC, Tsai LS, Chen SC, Lu SN*. Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both hepatitis B and C strains independently. J Gastroenterol Hepatol. 2010 Nov;25(11):1763-8. (SCI)

    • Tseng PL, Wang JH, Tung HD, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen PF, Tsai LS, Lu SN*. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol. 2010 Aug;25(8):1426-34. (SCI)

    • Kee KM, Hung CM, Wang JH, Hung CH, Chen PF, Lin KS, Lu SN*. Low accuracy of the national reporting system of acute hepatitis C infection in Taiwan, 1995-2004. J Gastroenterol Hepatol. 2010 Jul;25(7):1289-94. (SCI)

    • Wang JH, Changchien CS, Hung CH, Tung WC, Kee KM, Chen CH, Hu TH, Lee CM, Lu SN*. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan. J Gastroenterol Hepatol. 2010 May;25(5):964-9. (SCI)

    • Chang KC, Tsai PS, Hsu MC, Hung SF, Tsai CC, Lu SN*. Chronic hepatitis C increased the mortality rates of patients with hepatocellular carcinoma and diabetes mellitus in a triple hepatitis virus endemic community. J Gastroenterol. 2010 Jun;45(6):636-45. (SCI)

    • Tung HD, Wang JH, Tseng PL, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen YD, Lu SN*. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am J Gastroenterol. 2010 Mar;105(3):624-31. (SCI)
      Erratum in: Am J Gastroenterol. 2010 Jun;105(6):1455.
    • Tsai MC, Wang JH, Hung CH, Kee KM, Yen YH, Lee CM, Hu TH, Chen CH, Lu SN*. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2010 Mar;25(3):605-12. (SCI)

    • Su WW, Chen CH, Lin HH, Yang SS, Chang TT, Cheng KS, Wu JC, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Lu SN*. Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas. Hepatol Int. 2009 Dec;3(4):537-43. (SCI)

    • Chiang JC, Lin CY, Wang JH, Kee KM, Chen PF, Chen YD, Tsai LS, Chen TH, Lu SN*. Identifying hepatitis C virus: endemic areas and estimating the viral antibody prevalence based on the prevalence of ALT elevation. Trans R Soc Trop Med Hyg. 2009 Sep;103(9):917-23. (SCI)

    • Lin CY, Kee KM(co-first), Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lu SN*. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int. 2009 Jan;29(1):74-81. (SCI)

    • Yen YH, Changchien CS, Wang JH, Kee KM, Hung CH, Hu TH, Lee CM, Lin CY, Wang CC, Chen TY, Huang YJ, Lu SN*. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis. 2009 Jun;41(6):431-41. (SCI)

    • Wang JH, Changchien CS, Hung CH, Eng HL, Tung WC, Kee KM, Chen CH, Hu TH, Lee CM, Lu SN*. FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. J Gastroenterol. 2009;44(5):439-46. (SCI)

    • Huang YJ, Hsu HC, Wang CY, Wang CJ, Chen HC, Huang EY, Fang FM, Lu SN*. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1155-63. (SCI)

    • Kao JT, Wang JH, Hung CH, Yen YH, Hung SF, Hu TH, Lee CM, Lu SN*. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine. 2009 Mar 13;27(12):1858-62. (SCI)

    • Kao JT, Wang JH, Hung CH, Hu TH, Lee CM, Hung SF, Lu SN*. Changing aetiology of liver dysfunction in the new generation of a hepatitis B and C-endemic area: cross-sectional studies on adolescents born in the first 10 years after universal hepatitis B vaccination. Liver Int. 2008 Nov;28(9):1298-304. (SCI)

    • Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, Chen CL, Chen TY, Huang YJ, Lu SN*. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer. 2008 May;44(7):1000-6. (SCI)

    • Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, Wang CC, Cheng YF, Huang YJ, Lin CY, Lu SN*. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol. 2008;43(2):159-70. (SCI)

    • Lu SN, Yen YH, Lin CY, Kee KM, Wang JH, Changchien CS*. Clinical Staging of Hepatocellular Carcinoma. Journal of The Chinese Oncology Society 2008 Oct. 24(5):295-303. 中華民國癌症醫學會雜誌

    • Lu SN*, Wang JH, Chen PF, Tung HD, Tseng PL, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen YD, Tsai LS, Chen TH. Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults. Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1813-21. (SCI)